Humulin M3, 100me/ml cartridges, 3ml, 5pcs

Composition

>

1 ml of suspension for injection contains:

Active ingredient:

mixture of human soluble insulin and 100 U insulin suspension (30% human soluble insulin and 70% human isophane insulin suspension)

Pharmacological action

Humulin M 3 is a DNA-recombinant human insulin of medium duration of action. It is a two-phase suspension (30% Humulin Regular And 70% Humulin NPH).

The main effect of the drug is the regulation of glucose metabolism. In addition, it has an anabolic effect. In muscle and other tissues (with the exception of the brain), insulin causes rapid intracellular transport of glucose and amino acids, accelerates the anabolism of proteins. Insulin promotes the conversion of glucose to glycogen in the liver, inhibits gluconeogenesis, and stimulates the conversion of excess glucose to fat.

Pharmacokinetics

Humulin M 3 is a medium-acting insulin preparation.

The onset of action of the drug is 30 minutes after use, the maximum effect is between 1 and 8.5 hours, and the duration of action is 14-15 hours.

Individual differences in insulin activity depend on such factors as the dose, the choice of injection site, and the patient’s physical activity.

Indications

• diabetes mellitus in the presence of indications for insulin therapy;
• newly diagnosed diabetes mellitus;
• pregnancy with type 2 diabetes mellitus (non-insulin-dependent).

Use during pregnancy and lactation

During pregnancy and lactation, the need for insulin changes, which should be taken into account to maintain adequate metabolic control.

Insulin does not cross the placental barrier.

Contraindications

Hypoglycemia, insulinoma, hypersensitivity to this insulin.

Side effects

Side effects associated with the effect on carbohydrate metabolism: hypoglycemic conditions (pallor, increased sweating, palpitation, sleep disorders, tremor).

Allergic reactions: rarely-skin rash; extremely rarely-angioedema.

Local reactions: rarely-hyperemia and pruritus at the injection site of the drug; with prolonged use, rarely-lipodystrophy at the injection site.

Interaction

The hypoglycemic effect of insulin is enhanced by MAO inhibitors, non-selective beta-blockers, sulfonamides, anabolic steroids, tetracyclines, clofibrate, cyclophosphamide, fenfluramine; drugs containing ethanol.

The hypoglycemic effect of insulin is reduced by oral contraceptives, glucocorticoids, thyroid hormones, thiazide diuretics, heparin, lithium preparations, tricyclic antidepressants.

Under the influence of reserpine and salicylates, both a weakening and an increase in the action of insulin is possible.

Beta-blockers, clonidine, and reserpine may mask the symptoms of hypoglycemia.

Ethanol, various disinfectants can reduce the biological activity of insulin.

How to take, course of use and dosage

The dose is set by the doctor individually, depending on the level of glycemia.

The drug should be administered subcutaneously, possibly intramuscularly. Intravenous use of Humulin M 3 is contraindicated!

Subcutaneously, the drug is injected into the shoulder, thigh, buttock or abdomen. The injection site should be alternated so that the same site is used no more than about 1 time/month.

When administered subcutaneously, care must be taken to avoid getting into a blood vessel. After the injection, do not massage the injection site. Patients should be trained in the correct use of insulin injection devices.

Rules for preparation and use of the drug

Cartridges and vials of Humulin M3 should be rolled between the palms of your hands 10 times before use and swung, turning 180° also 10 times to resuspend the insulin until it looks like a homogeneous cloudy liquid or milk. Do not shake vigorously, as this may lead to foam formation, which may interfere with the correct dosage.

Cartridges and vials should be carefully checked. Do not use insulin if there are flakes in it after mixing, if solid white particles stick to the bottom or walls of the bottle, creating the effect of a frosty pattern.

The design of the cartridges does not allow their contents to be mixed with other insulins directly in the cartridge itself. The cartridges are not designed to be refilled.

The contents of the vial should be collected in an insulin syringe corresponding to the concentration of the administered insulin, and enter the desired dose of insulin in accordance with the doctor’s instructions.

When using cartridges, follow the manufacturer’s instructions for refilling the cartridge and attaching the needle. The drug should be administered in accordance with the instructions of the manufacturer of the pen.

Using the external needle cap, unscrew the needle immediately after insertion and safely destroy it. Removing the needle immediately after injection ensures sterility, prevents leakage, air ingress and possible clogging of the needle. Then put the cap on the handle.

Needles should not be reused. Needles and syringes should not be used by others. Cartridges and vials should be used until they are empty and then discarded.

Overdose

Symptoms: hypoglycemia, accompanied by lethargy, increased sweating, tachycardia, pallor of the skin, headache, trembling, vomiting, confusion.

Under certain conditions, such as long-term or intensive control of diabetes mellitus, the symptoms that are harbingers of hypoglycemia may change.

Treatment: Mild conditions of hypoglycemia can usually be relieved by ingesting glucose (dextrose) or sugar. You may need to adjust your insulin dose, diet, or physical activity.

Correction of moderate hypoglycemia can be performed by intramuscular or subcutaneous use of glucagon, followed by ingestion of carbohydrates.

Severe conditions of hypoglycemia, accompanied by coma, convulsions or neurological disorders, are stopped by intramuscular or subcutaneous use of glucagon or intravenous use of a concentrated glucose solution (dextrose). After regaining consciousness, the patient should be given food rich in carbohydrates, in order to avoid the re-development of hypoglycemia.

Special instructions

Switching from one type of insulin to another should be done under the control of blood glucose levels.

In case of an overdose of insulin, if the patient is conscious, it is necessary to enter glucose orally; in case of loss of consciousness, glucose is administered intravenously or glucagon subcutaneously, intravenously or intravenously.

Influence on the ability to drive motor vehicles and manage mechanisms

When transferring a patient to this insulin, a temporary decrease in the rate of psychomotor reactions is possible.

With the initial use of insulin, a change in its type, or in the presence of significant physical or mental stress, it is possible to reduce the speed of psychomotor reactions and the ability to concentrate.

Form of production

Suspension for injection

Storage conditions

In the refrigerator, at a temperature of 2-8 °C (do not freeze)

Shelf life

2 years

Active ingredient

Biphasic insulin (human genetically engineered)

Conditions of release from pharmacies

By prescription

Dosage form

solution for injection

Description

For adults as prescribed by a doctor, Nursing mothers as prescribed by a doctor, Children as prescribed by a doctor, Pregnant women as prescribed by a doctor

Indications

Type 1 Diabetes